Abstract
Objective: Bevacizumab has been shown to improve PFS in advanced epithelial ovarian cancer (OC), but long term effects of incorporating bev into first-line treatment remains controversial. The goal of this study was to assess the prognostic effect of first-line bev on response at the time of treatment for recurrence in advanced OC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
